FENNEC PHARMACEUTICALS INC. (FENC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 9M 18M 27M Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 170K Q1 '21: 0 Q1 '23: 1.7M Q2 '23: 3.3M Q3 '23: 6.5M Q4 '23: 10M Q1 '24: 25.4M Q2 '24: 7.3M Q3 '24: 7M Q4 '24: 7.9M Q1 '25: 8.8M Q2 '25: 9.7M Q3 '25: 12.5M Q4 '25: 13.8M Q1 '26: 15.1M Q2 '26: 17.9M Q4 '15 Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 3.5M 7M 10.5M Q1 '23: 1.6M Q2 '23: 3.2M Q3 '23: 6.2M Q4 '23: 9.1M Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating Income Quarterly

-10M -5M 0 5M 10M 15M Q3 '16: -564K Q4 '16: -1.1M Q1 '17: -771K Q2 '17: -1.5M Q3 '17: -2.2M Q4 '17: -2.5M Q1 '18: -1.8M Q2 '18: -2.7M Q3 '18: -2.8M Q4 '18: -3.1M Q1 '19: -2.7M Q2 '19: -4.8M Q3 '19: -1.9M Q4 '19: -3.7M Q1 '20: -3.8M Q2 '20: -4.8M Q3 '20: -5.9M Q4 '20: -3.3M Q1 '21: -4.9M Q2 '21: -3.9M Q3 '21: -4.2M Q4 '21: -4.2M Q1 '22: -3.5M Q2 '22: -5M Q3 '22: -7.9M Q4 '22: -6.1M Q1 '23: -5.3M Q2 '23: -4.7M Q3 '23: -1M Q4 '23: -1.8M Q1 '24: 13.7M Q2 '24: -5M Q3 '24: -5.2M Q4 '24: -934K Q1 '25: -808K Q2 '25: -2.7M Q3 '25: -189K Q4 '25: -2.6M Q1 '26: -119K Q2 '26: 1.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q3 '16: -502K Q4 '16: -1.1M Q1 '17: -806K Q2 '17: -1.6M Q3 '17: -2.4M Q4 '17: -2.3M Q1 '18: -1.6M Q2 '18: -2.6M Q3 '18: -2.7M Q4 '18: -3M Q1 '19: -2.6M Q2 '19: -4.7M Q3 '19: -1.8M Q4 '19: -3.6M Q1 '20: -3.8M Q2 '20: -4.8M Q3 '20: -6.2M Q4 '20: -3.2M Q1 '21: -4.7M Q2 '21: -4M Q3 '21: -4.2M Q4 '21: -4.4M Q1 '22: -3.7M Q2 '22: -5.1M Q3 '22: -8.1M Q4 '22: -6.9M Q1 '23: -6.1M Q2 '23: -5.4M Q3 '23: -1.9M Q4 '23: -28.5M Q1 '24: 12.8M Q2 '24: -5.6M Q3 '24: -5.7M Q4 '24: -2M Q1 '25: -1.2M Q2 '25: -3.2M Q3 '25: -638K Q4 '25: -4.8M Q1 '26: 201K Q2 '26: 2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 250K 500K 750K Q1 '23: 95K Q2 '23: 148K Q3 '23: 331K Q4 '23: 685K Q1 '23 Q2 '23 Q3 '23 Q4 '23

Operating Cash Flow Quarterly

-15M 0 15M 30M 45M Q3 '16: -544K Q4 '16: -611K Q1 '17: -675K Q2 '17: -688K Q3 '17: -958K Q4 '17: -1.3M Q1 '18: -1.7M Q2 '18: -1.6M Q3 '18: -1.6M Q4 '18: -2.9M Q1 '19: -2.5M Q2 '19: -2.8M Q3 '19: -2.2M Q4 '19: -1.6M Q1 '20: -3.7M Q2 '20: -3.1M Q3 '20: -5.4M Q4 '20: -3.3M Q1 '21: -3.6M Q2 '21: -4.4M Q3 '21: -3M Q4 '21: -3.2M Q1 '22: -2.9M Q2 '22: -3.4M Q3 '22: -5M Q4 '22: -6.8M Q1 '23: -5.6M Q2 '23: -3.9M Q3 '23: -2.8M Q4 '23: -4.9M Q1 '24: 39M Q2 '24: -8.4M Q3 '24: -2.2M Q4 '24: -1.5M Q1 '25: -4.3M Q2 '25: -3.7M Q3 '25: 1.5M Q4 '25: -6M Q1 '26: 2.4M Q2 '26: 50K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-1.4M -700K 0 700K 1.4M 2.1M Q1 '11: -1M Q2 '11: 1.8M Q3 '11: -636K Q4 '11: -767K Q1 '12: -578K Q2 '12: -1.1M Q3 '12: -726K Q4 '12: -557K Q1 '13: -407K Q2 '13: -889K Q3 '13: -469K Q4 '13: -445K Q1 '14: -378K Q2 '14: -410K Q3 '14: -443K Q1 '11 Q3 '11 Q1 '12 Q3 '12 Q1 '13 Q3 '13 Q1 '14 Q3 '14

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '13: 25.6M Q3 '13: 8.4M Q1 '14: 9.8M Q2 '14: 9.8M Q3 '14: 11.2M Q1 '15: 11.9M Q2 '15: 10.8M Q3 '15: 10.9M Q1 '16: 10.9M Q2 '16: 12.8M Q3 '16: 13.6M Q1 '17: 13.6M Q2 '17: 14.2M Q3 '17: 15.7M Q1 '18: 18.4M Q2 '18: 18.6M Q3 '18: 19M Q1 '19: 19.9M Q2 '19: 19.9M Q3 '19: 19.9M Q1 '20: 19.9M Q2 '20: 23.4M Q3 '20: 25.6M Q1 '21: 26M Q2 '21: 26M Q3 '21: 26M Q1 '22: 26M Q2 '22: 26.1M Q3 '22: 26.1M Q1 '23: 26.6M Q2 '23: 26.5M Q3 '23: 26.6M Q1 '24: 31.1M Q2 '24: 27.3M Q3 '24: 27.4M Q1 '25: 27.6M Q2 '25: 27.7M Q3 '25: 27.9M Q1 '26: 35.5M Q2 '26: 36.4M Q3 '14 Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.05 -0.70 -0.35 0.00 0.35 0.70 1.05 Q3 '16: -0.19 Q4 '16: -0.23 Q1 '17: -0.25 Q2 '17: -0.30 Q3 '17: -0.41 Q4 '17: -0.47 Q1 '18: -0.50 Q2 '18: -0.53 Q3 '18: -0.52 Q4 '18: -0.52 Q1 '19: -0.29 Q2 '19: -0.39 Q3 '19: -0.34 Q4 '19: -0.37 Q1 '20: -0.70 Q2 '20: -0.67 Q3 '20: -0.82 Q4 '20: -0.76 Q1 '21: -0.75 Q2 '21: -0.69 Q3 '21: -0.61 Q4 '21: -0.66 Q1 '22: -0.62 Q2 '22: -0.66 Q3 '22: -0.81 Q4 '22: -0.89 Q1 '23: -0.98 Q2 '23: -1.00 Q3 '23: -0.76 Q4 '23: -0.64 Q1 '24: -0.00 Q2 '24: 0.01 Q3 '24: -0.13 Q4 '24: -0.02 Q1 '25: -0.47 Q2 '25: -0.38 Q3 '25: -0.19 Q4 '25: -0.33 Q1 '26: -0.28 Q2 '26: -0.12 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.